This experience led Fisher to conclude AF was indeed frequently associated with stroke attributed to cerebral thrombosis, and the hemorrhagic infarction in such cases was related to lysis of cerebral emboli and reperfusion of the infarct.
At about the same time, beginning in 1946, Wright and Foley 3 at the New York Hospital-Cornell Medical Center showed that anticoagulation could prevent strokes originating from fibrillating atria in patients with mitral stenosis. This work was later extended to those with nonvalvular AF and was discussed by Wright at the First Princeton Conference. 4 However, the evidence for a pathogenetic role for AF, in the absence of mitral stenosis, was mixed and contradictory. This issue remained unsettled and in dispute for more than 20 years. Reflecting current thinking among cardiologists, in the 3rd edition (1966) of the classic cardiology text, Diseases of the Heart, C.K. Friedberg averred, emboli rarely arise in the fibrillating heart without rheumatic heart disease. Thus persisted the common notion, based on the clinical impression that in the absence of valvular heart disease, AF, a frequent occurrence in the elderly, was generally a benign condition.
Evidence to the contrary accumulated slowly on the pathological, clinical, and epidemiological studies. A detailed exposition of the accumulating evidence is chronicled in the proceedings of a symposium on atrial fibrillation held in Kiruna, Sweden, in June 1981. 5 Fisher reviews the status of the field at that time, reviewing the generally primitive, somewhat conflicting, and generally inconclusive clinical and pathological case-control studies, suggesting AF in the absence of rheumatic heart disease was a source of thrombus and the basis for systemic embolism, including cerebral infarction.
Sufficient evidence led Fisher to respond to an editorial on electric conversion of AF. He wrote a Letter to the Editor in The Lancet in June 1972. He outlined, with extraordinary brevity, the key features of stroke in patients with AF and suggested prevention with anticoagulation ( Figure 1 ). 6 The key points are: AF is not rare in patients >60 years of age; these patients were in relatively good health; they sustained a severe stroke as the initial event; and most had nonrheumatic heart disease.
To the accumulating pathological evidence and clinical experience, data from prospective epidemiological study of stroke in patients with AF became available. After 24 years of follow-up in the Framingham Heart Study, 345 documented strokes had occurred, 27 in subjects with chronic AF: 7 with rheumatic heart disease, and 20 with nonrheumatic AF. In patients with AF associated with rheumatic heart disease, the incidence of stroke was increased 17.6-fold, and in those with AF in the absence of valvular disease, there was a 5.6-fold increased stroke incidence. 7 The authors noted that the stroke events in 19 of the 20 chronic fibrillators had the clinical features commonly associated with embolic strokes: abrupt onset; maximal deficit at onset; absence of antecedent transient ischemic attacks; and whether recovery ensued a rapid reversal of the neurological signs. Pathological support for embolism was found in 6 of the 12 who died. With
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continued stroke surveillance and additional follow-up, it was possible to provide age-specific incidence rates of AF and the proportion of strokes associated with this arrhythmia. Overall, 14.7% of strokes in Framingham were associated with AF. Of great interest, AF accounted for an increasing proportion of strokes with advancing age climbing from 6.7% for 50 to 59 years of age to 36.2% for 80 to 89 years of age. 8 Because AF, in the absence of valvular disease, and stroke occurred frequently in patients with hypertension, congestive heart failure, and coronary heart disease, it had been suggested that these cardiovascular diseases rather than the chronic AF accounted for the increased stroke incidence and for the increasing incidence with advancing age. It was possible, using 34 years of follow-up, that 572 stroke events had occurred providing sufficient data to clarify the independent contribution of AF in these Framingham Study participants. Prevalence of AF increased with age, more than doubling in successive decades from 0.5% at 50 to 59 years of age, to 1.8% at 60 to 69 years of age, to 4.8% at 70 to 79 years of age, and 8.8% at 80 to 89 years of age. The age-adjusted incidence of stroke was increased in the presence of hypertension, coronary heart disease, congestive heart failure, and AF ( Figure 2 ). Incidence of stroke was greatest in patients with AF even after the effects of the other associated cardiac conditions were taken into account. In addition, the attributable risk of stroke within each decile of age was calculated to estimate the percentage of stroke events that could be eliminated if the specific cardiac malady was removed (Table) . In addition, the proportion of stroke events occurring with these conditions was also computed. Attributable risk of stroke increased significantly with age ( Figure 2 ). In contrast, the attributable risk of stroke resulting from the other cardiovascular conditions was not affected by age. In the oldest age group (80-89 years), attributable risk with AF of 23.5% approached that from hypertension. 9 A key step in relating nonrheumatic AF was taken by demonstrating warfarin anticoagulation could prevent stroke in a clinical trial. Prevention by warfarin anticoagulation was accomplished in a series of 5 randomized clinical trials, which clearly established the effectiveness of warfarin therapy. 10 Overall, a 68% reduction in risk occurred, and most of these trials had to be stopped early as the preventive effectiveness became apparent. For example, in the Boston Area Anticoagulation Trial in AF (BAATAF), there were 2 strokes in the 212 patients randomized to low-dose warfarin therapy when compared with 13 strokes in the 208 controls after an average follow-up of 2.2 years, representing an 86% relative risk reduction, with an incidence rate in the warfarin group of 0.41 per year versus 3.0 per year in the control group, with virtually no excess in major bleeding.
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Despite this remarkable trial outcome and incontrovertible evidence that warfarin prevented stroke in nonrheumatic AF presumably by preventing the formation of left atrial clots in the presence of stasis, an accompanying editorial expressed reservations and entertained alternative conclusions. However, as a possible example of the durability of a disproved but previously favored hypothesis, the authors seemed reluctant to attribute the remarkable outcome of the trial to the obvious. Emboli arising from aortic arch atheromata, left ventricular thrombi, mitral valve abnormalities, and cerebrovascular atherosclerosis were alternative stroke mechanisms and sites mentioned. Concern was also expressed about falls in elderly patients and the increased risk with warfarin, an obvious worry in this age group with anticoagulants and despite an absence of these events in the BATAAF trial subjects. Two decades later, it is clear that warfarin (and more recently an array of other anticoagulant agents) prevents stroke in patients with AF. This is clearly the single most powerful stroke prevention measure available and continues to increase in importance as the population ages and with the improved survival of patients with coronary heart disease and congestive heart failure, which form the cardiac substrate for AF.
Although it was fascinating to read about the early 1949 neuropathological observations in the autobiography of Fisher mentioned above, as a testimony to Fisher's wisdom and modesty, and in response to an interviewer's question, "But your work on hemorrhagic infarction and heart embolism was 
